

IN THE CLAIMS

Please amend the claims as follows:

Claim 1. (Currently Amended) A ~~crystal~~ of a hydrochloride of Crystalline N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl)urea monohydrochloric acid salt monohydrate, wherein said hydrochloride is a hydrochloric acid monoadduct and a monohydrate.

Claims 2-12. (Cancelled)

Claim 13. (Currently Amended) The ~~crystal~~ crystalline compound according to claim 1, wherein in powder X-ray diffractometry, the ~~crystal~~ crystalline compound has peaks with not less than 10% relative intensity at at least the following diffraction angles (2 $\theta$ ):

Table A-1

Diffraction angle (2 $\theta$ )

11.47  $\pm$  X

22.59  $\pm$  X

23.02  $\pm$  X

26.27  $\pm$  X

26.63  $\pm$  X

wherein X is 0 to 0.20.

Claim 14. (Currently Amended) The ~~crystal~~ crystalline compound according to claim 13, wherein the relative intensity in said diffraction angles (2 $\theta$ ) is not less than 15%.

Claim 15. (Currently Amended) The ~~crystal~~ crystalline compound according to claim 13, wherein the relative intensity in said diffraction angles (2 $\theta$ ) is not less than 20%.

Claim 16. (Currently Amended) The ~~crystal~~ crystalline compound according to claim 13, wherein the relative intensity in said diffraction angles (2 $\theta$ ) is not less than 25%.

Claim 17. (Currently Amended) The ~~crystal~~ crystalline compound according to claim 13, wherein the relative intensity in said diffraction angles (2 $\theta$ ) is not less than 30%.

Claim 18. (Currently Amended) The ~~erystal-crystalline compound~~ according to any one of claims 13 to 17, wherein X is 0 to 0.10.

Claim 19. (Currently Amended) The ~~erystal-crystalline compound~~ according to claim 1, wherein in powder X-ray diffractometry, the ~~erystal-crystalline compound~~ has peaks with not less than 10% relative intensity at at least the following diffraction angles (2θ):

Table B-1

Diffraction angle (2θ)

8.76 ± X

11.47 ± X

15.28 ± X

17.16 ± X

17.53 ± X

18.80 ± X

20.02 ± X

22.59 ± X

23.02 ± X

25.32 ± X

25.43 ± X

26.27 ± X

26.63 ± X

27.00 ± X

28.57 ± X

wherein X is 0 to 0.20.

Claim 20. (Currently Amended) The ~~erystal-crystalline compound~~ according to claim 19, wherein the relative intensity in said diffraction angles (2θ) is not less than 15%.

Claim 21. (Currently Amended) The ~~erystal-crystalline compound~~ according to claim 19, wherein the relative intensity in said diffraction angles (2θ) is not less than 20%.

Claim 22. (Currently Amended) The erystal-crystalline compound according to any one of claims 19 to 21, wherein X is 0 to 0.10:

Claim 23. (Currently Amended) The erystal-crystalline compound according to claim 1, wherein in powder X-ray diffractometry, the erystal-crystalline compound has the following diffraction angles (2θ) and relative intensities:

Table 1

Diffraction angle (2θ)	Relative intensity
8.76	22
11.47	100
15.28	21
17.16	21
17.53	23
18.80	21
20.02	25
22.59	35
23.02	37
25.32	29
25.43	23
26.27	36
26.63	32
27.00	29
28.57	28

Claim 51. (Currently Amended) A process for producing a erystal of hydrochloride of crystalline N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl)urea monohydrochloric acid salt monohydrate, wherein said hydrochloride is a hydrochloric acid monoadduct and a monohydrate, said process comprising the steps of:

adding hydrochloric acid and ethanol to a solution of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl)urea in an aprotic polar solvent; and precipitating crystals from the solution.

Claim 52. (Original) The process according to claim 51, wherein, in addition to hydrochloric acid and ethanol, water is further added.

Claim 53. (Previously Presented) The process according to claim 51, wherein said aprotic polar solvent is N,N-dimethylformamide or N,N-dimethylacetamide.

Claim 54. (Previously Presented) The process according to claim 51, wherein said hydrochloric acid has a concentration of 10 to 14 N.

Claim 55. (Previously Presented) The process according to claim 51, wherein in powder X-ray diffractometry, the crystal has peaks with not less than 10% relative intensity at at least the following diffraction angles (2θ):

Table A-1

Diffraction angle (2θ)

11.47 ± X

22.59 ± X

23.02 ± X

26.27 ± X

26.63 ± X

wherein X is 0 to 0.20.

Claims 56-73 (Cancelled)

Claim 74. (Previously Presented) The process according to claim 52, wherein said aprotic polar solvent is N,N-dimethylformamide or N,N-dimethylacetamide.

Claim 75. (Previously Presented) The process according to claim 52, wherein said hydrochloric acid has a concentration of 10 to 14 N.

Claim 76. (Previously Presented) The process according to claim 53, wherein said hydrochloric acid has a concentration of 10 to 14 N.

Claim 77. (Previously Presented) The process according to claim 52, wherein in powder X-ray diffractometry, the crystal has peaks with not less than 10% relative intensity at at least the following diffraction angles (2θ):

Table A-1

Diffraction angle (2θ)

11.47 ± X

22.59 ± X

23.02 ± X

26.27 ± X

26.63 ± X

wherein X is 0 to 0.20.

Claim 78. (Previously Presented) The process according to claim 53, wherein in powder X-ray diffractometry, the crystal has peaks with not less than 10% relative intensity at at least the following diffraction angles (2θ):

Table A-1

Diffraction angle (2θ)

11.47 ± X

22.59 ± X

23.02 ± X

26.27 ± X

26.63 ± X

wherein X is 0 to 0.20.

Claim 79. (Previously Presented) The process according to claim 54, wherein in powder X-ray diffractometry, the crystal has peaks with not less than 10% relative intensity at at least the following diffraction angles (2θ):

Table A-1

Diffraction angle (2θ)

11.47 ± X

22.59 ± X

23.02 ± X

Application No. 10/532,104  
Preliminary Amendment

$26.27 \pm X$

$26.63 \pm X$

wherein X is 0 to 0.20.